Future to develop more assays for Bayer:
This article was originally published in Clinica
Future Diagnostics has won a contract from Bayer Healthcare's diagnostics division to develop a suite of immunoassays for use on the German multinational's line of Advia Centaur analyser systems. In the first phase of the agreement, Future Diagnostics, of Wijchen, the Netherlands, will develop four immunoassays: two fertility tests - one for sex hormone-binding globulin (SHBG) and another for dehydroepiandrosterone sulfate (DHEA); an unconjugated estriol (uE3) test to monitor foetal maturity and well-being; and an assay that detects the D-dimer marker linked to deep vein thrombosis or pulmonary embolism. Future Diagnostics had a previous agreement with Bayer in 2001, when it developed an intact parathyroid (PTH) assay for diagnosis of metabolic bone disease.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.